Oliclinomel N4-550 E

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin, the active ingredient in Oliclinomel N4-550 E, is a mixture of essential and non‑essential amino acids presented as a sterile powder for intravenous use. It supports metabolic and nutritional needs in patients requiring specialized amino‑acid supplementation.

GNH USA supplies Oliclinomel N4-550 E as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Oliclinomel N4-550 E is used primarily for amino‑acid supplementation in clinical situations that affect protein metabolism: - Post‑operative recovery: helps to promote recovery by providing the building blocks of protein synthesis in the post‑surgical patient. - Severe malnutrition: assists in restoring nitrogen balance and support of muscle mass when dietary intake is insufficient. - Inherited metabolic disorders such as phenylketonuria (PKU) or other branched‑chain amino‑acid deficiencies where target amino‑acid profiles are required to manage the disorder. - Critical‑illness ICU care: provides targeted amino‑acid support to critically ill patients to maintain lean body tissue and immune function. - Liver disease and hepatic failure in patients with impaired protein synthesis and in need of amino‑acid replacement for nutrition support .

Adverse reactions to Oliclinomel N4-550 E are generally mild and related to the intravenous route.

Common Side Effects: - Injection site erythema: mild redness of the injection site. - Transient headache : temporary headache during or after infusion. - Nausea: occasional feeling of queasiness or vomiting . - Mild hyperglycemia: slight increase in blood glucose levels. - Electrolyte shift : minor changes in serum potassium or sodium levels.

Serious or Rare Side Effects: - Anaphylactic reaction: severe, potentially life‑threatening allergic response. - Acute renal failure : rapid decline in kidney function requiring intervention. - Severe hyperammonemia: marked increase in blood ammon levels that can affect brain function. - Thrombotic events : blood clot formation in veins or arteries. - Metabolic acidosis : significant acid‑base imbalance requiring medical management.

When using Oliclinomel N4-550 E, clinicians should consider several safety measures: - Renal function monitoring: assess the patient for renal impairment before and during therapy. - Hepatic function assessment: evaluate liver status to avoid exacerbation of metabolic disorders. - Electrolyte balance: check serum electrolytes regularly, especially potassium and sodium. - Allergic history: verify any previous allergic reactions to amino‑acid solutions. - Metabolic monitoring: observe for signs of hyperammonemia or acid‑base disturbances. - Store at ambient temperature: keep the powder in its original container away from moisture.

Oliclinomel N4-550 E may interact with other therapies that affect amino‑acid metabolism or renal clearance:

Major Interactions (Avoid): - High‑dose glutamine supplementation: may increase nitrogen load and risk of hyperammonemia. - Nephrotoxic antibiotics: concurrent use can worsen renal impairment.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycemic agents: may require dose adjustment due to transient hyperglycemia. - Diuretics: can alter electrolyte balance when combined with amino‑acid infusion. - Parenteral lipid‑emulsion of the same formulation : risk of incompatibility in Y‑Y mixing devices. - Citrate c